Breast cancer burden in Africa: evidence from GLOBOCAN 2018

2020 ◽  
Author(s):  
Rajesh Sharma
Keyword(s):  
Breast Cancer ◽  
Central African Republic ◽  
The Gambia ◽  
Limited Resources ◽  
African Countries ◽  
Cancer Burden ◽  
Stage Disease ◽  
Incidence And Mortality ◽  
Standardized Mortality Rate ◽  
Mortality Estimates

Abstract Background Breast cancer is the leading malignancy in African females. This study aims to examine the breast cancer burden in Africa using recently released GLOBOCAN 2018 estimates. Methods The incidence and mortality estimates of age- and country-wise burden of breast cancer in 54 African countries were obtained from GLOBOCAN 2018. Results In Africa, breast cancer caused 74 072 deaths, and 168 690 cases were estimated to have occurred in 2018. The age-standardized incidence rate stood at 37.9/100 000 in Africa, varying from 6.9/100 000 in the Gambia to 69.6/100 000 in Mauritius. The age-standardized mortality rate stood at 17.2/100 000 in 2018, ranging from 4/100 000 in the Gambia to 29.1/100 000 in Somalia in 2018. Nigeria was the leading country in terms of absolute burden with 26 310 cases and 11 564 deaths, followed by Egypt with 23 081 new cases and 9254 deaths. The mortality-to-incidence ratio for Africa stood at 0.44, varying from 0.24 in Libya to 0.68 in the Central African Republic. Conclusion To tackle breast cancer burden in Africa, the main challenges are late-stage disease presentation, lack of screening and therapeutic infrastructure, lack of awareness and limited resources.

scholarly journals Epidemiology of Liver Cancer in Africa: Current and Future Trends

2019 ◽  
Vol 40 (02) ◽  
pp. 111-123
Author(s):  
Edith Okeke ◽  
Pantong Mark Davwar ◽  
Lewis Roberts ◽  
Kurt Sartorius ◽  
Wendy Spearman ◽  
...  
Keyword(s):  
Risk Factors ◽  
Hepatitis B ◽  
Viral Hepatitis ◽  
Sub Saharan Africa ◽  
Limited Resources ◽  
Hepatitis B Vaccination ◽  
Future Trends ◽  
Global Public Health ◽  
African Countries ◽  
Incidence And Mortality

AbstractHepatocellular carcinoma (HCC) is a disease of global public health significance with mortality on the rise, despite the preventable nature of its risk factors especially in Africa. It is now the sixth most common cancer worldwide, fifth in males, and ninth in females. HCC incidence and mortality are predicted to increase in African countries constrained by limited resources to combat endemic levels of viral infection and synergistic environmental risk factors. The changing nature of HCC etiology is particularly illustrated here with the traditional risk factors like viral hepatitis coexisting alongside high human immunodeficiency virus (HIV) prevalence and rapidly increasing urbanization that have promoted a sharp increase in additional risk factors like coinfection, type 2 diabetes mellitus, and obesity. Although there are some differences in etiology between North Africa and sub-Saharan Africa, risk factors like chronic viral hepatitis B and C, aflatoxin exposure, and iron overload predominate. Aggressive hepatitis B genotypes, combined with hepatitis B virus/hepatitis C virus/HIV coinfections and aflatoxin exposure, promote a more aggressive molecular phenotype. In parallel to a better understanding of the molecular etiology of HCC, policy and planning initiatives to address the burden of HCC must be anchored within the reality of the limited resources available. Establishment and coordination of cancer registries across Africa is needed to improve the quality of data necessary to galvanize action. Preventive measures including hepatitis B vaccination programs, measures to prevent maternal-to-child and child-to-child transmission, delivery of universally accessible antiretroviral and antiviral treatments, and reduction of dietary aflatoxin exposure can contribute markedly to reduce HCC incidence. Finally, the development of biomarkers and new therapeutic interventions will need a better understanding of the unique genetic and epigenetic characteristics of HCC on the continent. We present a narrative review of HCC in Africa, discussing present and future trends.

scholarly journals COVID-19 pandemic in the African continent: Forecasts of cumulative cases, new infections, and mortality

2020 ◽  
Author(s):  
T Achoki ◽  
U Alam ◽  
L Were ◽  
T Gebremedhin ◽  
F Senkubuge ◽  
...  
Keyword(s):  
Central Africa ◽  
Population Level ◽  
Eastern Africa ◽  
Local Context ◽  
African Countries ◽  
Enabling Factors ◽  
Western Africa ◽  
Incidence And Mortality ◽  
The Impact ◽  
Mortality Estimates

BackgroundThe epidemiology of COVID-19 remains speculative in Africa. To the best of our knowledge, no study, using robust methodology provides its trajectory for the region or accounts for local context. This paper is the first systematic attempt to provide prevalence, incidence, and mortality estimates across Africa.MethodsCaseloads and incidence forecasts are from a co-variate-based instrumental variable regression model. Fatality rates from Italy and China were applied to generate mortality estimates after making relevant health system and population-level characteristics related adjustments between each of the African countries.ResultsBy June 30 2020, around 16.3 million people in Africa will contract COVID-19 (95% CI 718,403 to 98,358,799). Northern and Eastern Africa will be the most and least affected areas. Cumulative cases by June 30 are expected to reach around 2.9 million (95% CI 465,028 to 18,286,358) in Southern Africa, 2.8 million (95% CI 517,489 to 15,056,314) in Western Africa, and 1.2 million (95% CI 229,111 to 6,138,692) in Central Africa. Incidence for the month of April 2020 is expected to be highest in Djibouti, 32.8 per 1000 (95% CI 6.25 to 171.77), while Morocco will experience among the highest fatalities (1,045 deaths, 95% CI 167 to 6,547).ConclusionLess urbanized countries with low levels of socio-economic development (hence least connected to the world), are likely to register lower and slower transmissions at the early stages of an epidemic. However, the same enabling factors that worked for their benefit can hinder interventions that have lessened the impact of COVID-19 elsewhere.

scholarly journals Survival Outcomes of Breast Cancer in Sudanese Women: A Hospital-Based Study

2021 ◽  
pp. 324-332
Author(s):  
Hiba F. Muddather ◽  
Moawia M. A. Elhassan ◽  
Areeg Faggad
Keyword(s):  
Breast Cancer ◽  
Clinical Stage ◽  
Advanced Stage ◽  
Survival Times ◽  
African Countries ◽  
Curative Intent ◽  
Central Sudan ◽  
Raising Awareness ◽  
Stage Disease ◽  
Clinicopathologic Factors

PURPOSE Breast cancer (BC) is the leading malignancy among Sudanese women. Yet, data on survival are limited. This study aimed to determine 5-year overall survival (OS) of BC in Sudanese women, and identify prognostic demographic and clinicopathologic factors. PATIENTS AND METHODS A hospital-based retrospective study was conducted by reviewing data of women with BC diagnosed and treated at the National Cancer Institute—University of Gezira during 2012, and followed up to end of August 2018. Data were retrieved from medical records and analyzed, OS was determined, and the prognostic factors were explored. RESULTS A total of 225 cases were recruited. The median age at presentation was 45 years (range, 22-85 years). Clinical stage I, II, III, and IV represented 3.1%, 31.6%, 48%, and 17.3%, respectively. Most women (81.3%) were treated with curative intent. Of those, 25.1% received neoadjuvant chemotherapy. Mastectomy was the commonest (61.7%) type of surgery. The median follow-up period was 59.8 months with mean OS time of 55.7 months. The 5-year cumulative survival rate was 58%. The 5-year OS rates for stages I, II, III, and IV were 71.5%, 82.4%, 56.5%, and 8.4%, respectively. For lymph node (LN)-positive cases, 5-year OS rate was 63% and for LN-negative was 83.5%. Presenting with advanced-stage disease and positive LN status associated with short OS times ( P < .005). CONCLUSION OS of women with BC in Central Sudan is worse than in the developed world, but similar to African countries. Our findings indicate that advanced stage at diagnosis and lymph nodal involvement are strong predictors of short survival times. Raising awareness and introducing early detection programs are critical for better survival of these patients.

scholarly journals The European cancer burden in 2020: Incidence and mortality estimates for 40 countries and 25 major cancers

2021 ◽  
Vol 157 ◽  
pp. 308-347
Author(s):  
Tadeusz Dyba ◽  
Giorgia Randi ◽  
Freddie Bray ◽  
Carmen Martos ◽  
Francesco Giusti ◽  
...  
Keyword(s):  
Cancer Burden ◽  
Incidence And Mortality ◽  
Mortality Estimates ◽  
European Cancer

scholarly journals Breast Cancer burden in Tunisia: situation in 2017 and projections by 2030

2019 ◽  
Vol 29 (Supplement_4) ◽  
Author(s):  
A Cherif ◽  
S Dhaouadi ◽  
M Osman ◽  
M Hsairi
Keyword(s):  
Breast Cancer ◽  
Screening Program ◽  
Demographic Data ◽  
Breast Cancer Incidence ◽  
Premature Mortality ◽  
Epidemiological Data ◽  
Cancer Burden ◽  
Effective Interventions ◽  
Life Years ◽  
Incidence And Mortality

Abstract Introduction Despite advances in diagnostic and treatment of cancer, burden of this disease is increasing worldwide. Breast Cancer is one of the leading cancers and major causes of death among female worldwide. The aim of this study was to describe the breast cancer burden in Tunisia in terms of disability adjusted life years (DALY) in 2017 and to perform projections by 2030. Methods DALYs for cancer are the sum of years of potential life lost due to premature mortality (Years Life Lost (YLL) and the years lived with disability (YLD). We used epidemiological data (incidence rate, death rate, DALY, YLL and YLD) estimated by the Institute for Health Metrics and Evaluation (IHME). Demographic data were provided by the National institute of statistics. The projection of DALYs for breast cancer through 2030 was performed by a Poisson Regression analysis with Age -Period -Cohort (APC) using SPSS software while using IHME estimated data for the period 1990-2017. Results In 2017, breast cancer incidence and mortality rate among females in Tunisia were 50.17/100000 persons years and 14.04/100000 persons years respectively. Breast cancer DALY values were 25145 (438 /100000 persons years). The percentage of YLL in DALYS was 92.4%. Without effective interventions, the number of DALYs due to breast cancer would reach 40071 in 2030 with a standardized rate of 507/100000 persons years (IC 95% = [501/100000 to 514/100000]. The number of YLL predicted will attain 36457 with a standardized rate of 461/100000 persons years. Conclusions The burden of breast cancer among Tunisian women in 2017 is relatively high mainly due to the lack of screening program. There is an urgent need of a strong plan of early detection and appropriate care. Key messages Burden of breast cancer among women in 2017 is high and will rise in 2030. Renforcing screening program is urgent.

scholarly journals Delays in Breast Cancer Detection and Treatment in Developing Countries

2018 ◽  
Vol 12 ◽  
pp. 117822341775267 ◽  
Author(s):  
Monica M Rivera-Franco ◽  
Eucario Leon-Rodriguez
Keyword(s):  
Breast Cancer ◽  
Developing Countries ◽  
Survival Data ◽  
Survival Rates ◽  
The United States ◽  
Middle Income ◽  
Common Cancer ◽  
Stage Disease ◽  
Incidence And Mortality ◽  
Few Data

Breast cancer is the most common cancer in women in both developed and developing countries and the second most common cancer in the world. Developing countries are increasingly adopting a Western lifestyle, such as changes in diet and delayed first childbirth, lower parity, and shorter periods of breastfeeding, which are important determinants of a higher incidence of breast cancer among those regions. Low- and middle-income countries (LMICs) represent most of the countries with the highest mortality rates, ranging from 40% to 60%. Furthermore, developing countries account for scarce survival data, and the few data available coincide with the observed incidence and mortality differences. Five-year survival rates for breast cancer are much worse for LMICs countries such as Brazil, India, and Algeria in comparison with the United States and Sweden. Paucity of early detection programs explain these poor survival rates, which results in a high proportion of women presenting with late-stage disease, along with lack of adequate diagnosis and treatment facilities. Emphasis is urgently needed on health education, to promote early diagnosis of breast cancer, highlighting the importance of creating more public facilities that provide treatment, which are key components for the improvement in breast cancer care in developing countries.

scholarly journals Epidemics of serogroup ANeisseria meningitidisof subgroup III in Africa, 1989–94

1996 ◽  
Vol 116 (2) ◽  
pp. 115-120 ◽  
Author(s):  
M. Guibourdenche ◽  
E. A. Høiby ◽  
J.-Y. Riou ◽  
F. Varaine ◽  
C. Joguet ◽  
...  
Keyword(s):  
Neisseria Meningitidis ◽  
Central African Republic ◽  
Systemic Disease ◽  
The Gambia ◽  
Enzyme Electrophoresis ◽  
The South ◽  
African Countries ◽  
The West ◽  
Multilocus Enzyme Electrophoresis

SUMMARYA total of 125 strains ofNeisseria meningitidisrecovered in the course of outbreaks from patients with systemic disease in 11 African countries between 1989 and 1994 were analysed by serogrouping, serotyping and multilocus enzyme electrophoresis. Of the 125 patient strains 115 (92%) belonged to the clone-complex of serogroup A meningococci, designated subgroup III. Among the remaining strains, 4 were also serogroup A, but belonged to the clonal groups I and IV-1 (2 strains each), whilst 6 strains (4 serogroup C and 2 serogroup W135) represented clones of the ET-37 complex. Our results indicated that the second pandemic caused by clones of subgroup III is still spreading in Africa. Towards the West it has reached Niger, Mali, Guinea and The Gambia, and towards the South, the Central African Republic, Uganda, Rwanda, Burundi, Tanzania and Zambia.

Anticancer Potential of Calli Versus Seedling Extracts Derived from Rosmarinus officinalis and Coleus hybridus

2020 ◽  
Vol 21 (14) ◽  
pp. 1528-1538
Author(s):  
Sarah Albogami ◽  
Hadeer Darwish ◽  
Hala M. Abdelmigid ◽  
Saqer Alotaibi ◽  
Ahmed Nour El-Deen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Breast Cancer Cells ◽  
Transcriptional Profiling ◽  
Significant Inhibition ◽  
Rosmarinus Officinalis ◽  
Crude Extracts ◽  
Incidence And Mortality ◽  
Mcf 7

Background: In Saudi Arabia, the incidence and mortality rates of breast cancer are high. Although current treatments are effective, breast cancer cells develop resistance to these treatments. Numerous studies have demonstrated that active compounds in plant extracts, such as the phenolic compound Rosmarinic Acid (RA), exert anti-cancer effects. Objective: We investigated the anticancer properties of methanolic crude extracts of seedlings and calli of Rosmarinus officinalis and Coleus hybridus, two Lamiaceae species. Methods: MCF-7 human breast cancer cells were treated with methanolic crude extracts obtained from plant calli and seedlings generated in vitro, and cell proliferation was evaluated. Transcriptional profiling of the seedling and callus tissues was also conducted. Results: The mRNA expression levels of RA genes were higher in C. hybridus seedlings than in R. officinalis seedlings, as well as in C. hybridus calli than in R. officinalis calli, except for TAT and C4H. In addition, seedling and callus extracts of both R. officinalis and C. hybridus showed anti-proliferative effects against MCF-7 cells after 24 or 48 h of treatment. Discussion: At a low concentration of 10 μg/mL, C. hybridus calli and seedling extracts showed the most significant anti-proliferative effects after 24 and 48 h of exposure (p < 0.01); controls (doxorubicin) also showed significant inhibition, but lesser than that observed with C. hybridus (p < 0.05). Results with R. officinalis callus and seedling extracts did not significantly differ from those with untreated cells. Conclusion: Methanolic extracts of R. officinalis and C. hybridus are potentially valuable options for breast cancer treatment.

Identification of biomarkers and functional modules from genomic data in stage-wise breast cancer

2020 ◽  
Vol 15 ◽  
Author(s):  
Athira K ◽  
Vrinda C ◽  
Sunil Kumar P V ◽  
Gopakumar G
Keyword(s):  
Breast Cancer ◽  
Expression Patterns ◽  
Differential Expression Analysis ◽  
Predictive Biomarkers ◽  
Stage I ◽  
Stage Ii ◽  
Stage Iii ◽  
Functional Modules ◽  
Incidence And Mortality ◽  
Multiple Stages

Background: Breast cancer is the most common cancer in women across the world, with high incidence and mortality rates. Being a heterogeneous disease, gene expression profiling based analysis plays a significant role in understanding breast cancer. Since expression patterns of patients belonging to the same stage of breast cancer vary considerably, an integrated stage-wise analysis involving multiple samples is expected to give more comprehensive results and understanding of breast cancer. Objective: The objective of this study is to detect functionally significant modules from gene co-expression network of cancerous tissues and to extract prognostic genes related to multiple stages of breast cancer. Methods: To achieve this, a multiplex framework is modelled to map the multiple stages of breast cancer, which is followed by a modularity optimization method to identify functional modules from it. These functional modules are found to enrich many Gene Ontology terms significantly that are associated with cancer. Result and Discussion: predictive biomarkers are identified based on differential expression analysis of multiple stages of breast cancer. Conclusion: Our analysis identified 13 stage-I specific genes, 12 stage-II specific genes, and 42 stage-III specific genes that are significantly regulated and could be promising targets of breast cancer therapy. That apart, we could identify 29, 18 and 26 lncRNAs specific to stage I, stage II and stage III respectively.

Serum Carboxypeptidase N1 Serves as a Potential Biomarker Complementing CA15-3 for Breast Cancer

2020 ◽  
Vol 20 (17) ◽  
pp. 2053-2065
Author(s):  
Ranliang Cui ◽  
Chaomin Wang ◽  
Qi Zhao ◽  
Yichao Wang ◽  
Yueguo Li
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Critical Concentration ◽  
Tumour Size ◽  
Clinical Stage ◽  
Metastatic Breast ◽  
Breast Cancer Patients ◽  
Potential Biomarker ◽  
Incidence And Mortality ◽  
Combined Detection

Background: The incidence and mortality of breast cancer are increasing annually. Breast cancer seriously threatens women's health and quality of life. We aimed to measure the clinical value of CPN1, a new serum marker of breast cancer and to evaluate the efficacy of CPN1 in combination with CA15-3. Methods: Seventy samples of breast cancer with lymph node metastasis, seventy-three samples of nonmetastatic breast cancer and twenty-five samples of healthy human serum were collected. Serum CA15-3 concentration was determined by Roche Elecsys, and serum CPN1 concentration was determined by ELISA. Results: In breast cancer patients, serum CPN1 concentration was positively correlated with tumour size, clinical stage and CA15-3 concentration (r = 0.376, P<0.0001). ROC curve analysis showed that the optimal critical concentration of CPN1 for breast cancer diagnosis was 32.8pg/ml. The optimal critical concentration of CPN1 in the diagnosis of metastatic breast cancer was 66.121pg/ml. CPN1 has a greater diagnostic ability for breast cancer (AUCCA15-3=0.702 vs. AUCCPN1=0.886, P<0.0001) and metastatic breast cancer (AUCCA15-3=0.629 vs. AUCCPN1=0.887, P<0.0001) than CA15-3, and the combined detection of CA15-3 and CPN1 can improve the diagnostic efficiency for breast cancer (AUCCA15-3+CPN1=0.916) and for distinguishing between metastatic and non-metastatic breast cancer (AUCCA15-3+CPN1=0.895). Conclusion: CPN1 can be used as a new tumour marker to diagnose and evaluate the invasion and metastasis of breast cancer. The combined detection of CPN1 and CA15-3 is more accurate and has a certain value in clinical application.

Sign in / Sign up

Export Citation Format

Share Document